Elicio Therapeutics shares are trading lower after the company announced interim data from the ongoing Phase 1 study of ELI-002 in patients with mutant KRAS-driven tumors at high risk for relapse at the 2023 ASCO Meeting.
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics announced interim data from the ongoing Phase 1 study of ELI-002 in patients with mutant KRAS-driven tumors at high risk for relapse at the 2023 ASCO Meeting, causing its shares to trade lower.
June 05, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Elicio Therapeutics shares are trading lower after announcing interim data from the ongoing Phase 1 study of ELI-002 in patients with mutant KRAS-driven tumors.
The announcement of interim data from the ongoing Phase 1 study of ELI-002 in patients with mutant KRAS-driven tumors at high risk for relapse has led to a decline in Elicio Therapeutics' share price. This is likely due to investor concerns about the potential efficacy and safety of the treatment, as well as the overall progress of the study.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100